Orphanet: SAPPHIRE Efficacy and safety of AP 12009 Trabedersen in adult patients with recurrent or refractory Anaplastic Astrocytoma WHO grade III as compared to standard treatment with Temozolomide or BCNU a randomized actively controlled open label Phase III Study coordination
x

Cerca un network

* (*) campo obbligatorio

SAPPHIRE : Efficacy and safety of AP 12009 (Trabedersen) in adult patients with recurrent or refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU : a randomized, actively controlled, open-label Phase III Study (coordination)

SAPPHIRE : Efficacy and safety of AP 12009 (Trabedersen) in adult patients with recurrent or refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU : a randomized, actively controlled, open-label Phase III Study (coordination)

  • Tipo di network : Sperimentazioni cliniche internazionali
  • Distribuzione geografica : Mondiale
  • Ente(-i) finanziatore(-i) : -
  • Sponsor : Isarna therapeutics gmbh
  • Sito web
Ultimo aggiornamento: Marzo 2011

Partecipanti

Informazioni supplementari

Tutte le informazioni presenti nel sito non sostituiscono in alcun modo il giudizio di un medico specialista, l'unico autorizzato ad effettuare una consulenza medica ed esprimere un parere medico.